NCT06763315View on ClinicalTrials.gov

Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

October 31, 2028

Conditions
Plexiform Neurofibromas (PN)
Interventions
DRUG

Selumetinib

Use of the internationally recommended standard dose and low dose of the same drug

Trial Locations (1)

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER